Bacterin, developer of bone graft material, has priced $65 million aggregate principle amount of convertible senior unsecured notes due 2021.
Here are five key points:
1. The investment banking firm serving as initial purchaser has the option to purchase another $9.75 million aggregate principal amount of notes.
2. The notes will be sold to "qualified institutional buyers."
3. They will be unsecured, unsubordinated obligations of the company. The notes will have an interest at a rate of 6 percent per year.
4. Bacterin estimates that net proceeds will be about $62.8 million.
5. Bacterin plans to put the net proceeds of the offering towards funding the cash portion of the purchase price of the acquisition of X-spine Systems.